Tagrisso 80 mg is a prescription targeted anticancer medicine containing osimertinib. It is used in specific treatment settings involving non-small cell lung cancer (NSCLC) with certain epidermal growth factor receptor (EGFR) mutations. By inhibiting susceptible mutant EGFR proteins, osimertinib interferes with signaling pathways that contribute to cancer-cell growth and survival.
The medicine has different roles depending on the stage of cancer, molecular test results and previous treatment. It may be used after surgery, following definitive chemoradiation in selected patients, or for locally advanced or metastatic disease. In certain approved settings, it may be prescribed with other anticancer medicines.
This page explains the principal uses of Tagrisso 80 mg, how treatment decisions are made, what patients may expect during therapy and which precautions are important.
What Is Tagrisso 80 mg?
Tagrisso is the brand name associated with osimertinib, an oral EGFR tyrosine kinase inhibitor. The 80 mg strength refers to the amount of active ingredient in each tablet of the product described here.
EGFR is a protein involved in signaling processes that regulate cell growth and survival. Certain mutations can cause abnormal signaling that contributes to the development and progression of lung cancer. Osimertinib targets susceptible mutant forms of this protein.
Tagrisso is not a general treatment for every lung cancer. Appropriate use depends on the specific indication, the tumor’s molecular characteristics and the patient’s clinical circumstances.
1. Adjuvant Treatment After Lung Cancer Surgery
One use of osimertinib is adjuvant treatment for eligible patients with resected NSCLC harboring specified EGFR mutations.
Adjuvant treatment is given after the primary tumor has been surgically removed. Its purpose is to reduce the risk of cancer recurrence in patients who meet the relevant eligibility criteria.
Surgery does not eliminate the possibility of recurrence in every patient. Microscopic cancer cells may remain even when no visible tumor is detected. The potential benefit of additional treatment depends on the patient’s tumor characteristics, pathology findings and clinical circumstances.
The oncology team evaluates the molecular test results and other relevant information before recommending adjuvant osimertinib. The decision should also consider potential adverse reactions, treatment burden and the patient’s preferences.
Tagrisso cannot guarantee that cancer will not return. Patients should discuss the intended treatment duration, expected benefits, uncertainties and monitoring plan with their oncologist.
2. Treatment Following Definitive Chemoradiation
In certain approved settings, osimertinib may be used for eligible patients with unresectable stage III NSCLC harboring an appropriate EGFR mutation after definitive chemoradiation.
Chemoradiation combines chemotherapy and radiation therapy as part of a treatment plan intended to control cancer in the chest. Some patients may have disease that cannot be completely removed through surgery.
Following definitive chemoradiation, the oncology team assesses whether additional targeted treatment is appropriate. The decision depends on the patient’s clinical status, molecular results, prior treatment and the applicable approved indication.
This treatment setting differs from adjuvant therapy after surgery and from treatment of metastatic disease. Eligibility criteria and treatment objectives should not be assumed to be identical.
Patients should ask their healthcare professional to explain why osimertinib is being recommended, what benefit is expected and how treatment response and adverse reactions will be monitored.
3. First-Line Treatment of Advanced EGFR-Mutated NSCLC
Tagrisso is used as a first-line treatment option for eligible patients with locally advanced or metastatic NSCLC harboring specified EGFR mutations.
First-line treatment means the initial systemic treatment used for the relevant advanced-disease setting. The aim is to control cancer growth, delay progression and help manage the effects of the disease.
Osimertinib targets susceptible EGFR mutations, including common activating mutations such as exon 19 deletions and exon 21 L858R substitutions.
In certain approved first-line settings, osimertinib may also be used with pemetrexed and platinum-based chemotherapy. The choice between an appropriate treatment regimen depends on the applicable authorization, clinical evidence, disease characteristics, the patient’s overall health and individual treatment goals.
The oncology team should explain the expected advantages and limitations of the proposed regimen, including the possible additional adverse reactions associated with combination treatment.
4. Treatment of EGFR T790M Mutation-Positive Disease
Osimertinib has activity against the EGFR T790M resistance mutation, which can contribute to resistance to certain earlier EGFR-targeted medicines.
In the applicable clinical and regulatory settings, Tagrisso may be used for selected patients with advanced NSCLC whose tumors test positive for this mutation following progression on or after previous EGFR-targeted therapy.
The treating oncologist determines whether further molecular testing is appropriate and whether the results support the intended treatment.
Not every patient whose cancer progresses after an earlier targeted medicine will have a T790M mutation. Progression may arise through different biological mechanisms, so treatment selection requires reassessment rather than an assumption that osimertinib is appropriate in every case.
The relevant indication and eligibility requirements should be confirmed against current local prescribing information.
How Does Tagrisso Work in Lung Cancer?
Osimertinib inhibits the tyrosine kinase activity of susceptible mutant EGFR proteins. This reduces abnormal signaling that can support cancer-cell growth and survival.
Its activity against specific EGFR mutations makes molecular testing important when determining whether the medicine is suitable.
Although Tagrisso is a targeted treatment, it can still affect normal tissues and cause adverse reactions. Targeted therapy does not mean that treatment is free from risk.
Cancer cells may also develop resistance over time. If the disease progresses, the oncology team may reassess the patient’s condition and consider whether additional testing or another treatment strategy is appropriate.
Who May Be Eligible for Tagrisso 80 mg?
Eligibility depends on the approved treatment indication and the patient’s clinical circumstances. Important factors may include:
- Confirmation of NSCLC through appropriate diagnostic assessment.
- Molecular test results identifying a mutation relevant to the intended indication.
- The stage and characteristics of the cancer.
- Previous treatment, including surgery, chemotherapy, radiation therapy or earlier targeted medicines.
- The patient’s overall health and relevant medical history.
- Potential interactions and risks associated with other medicines.
- The applicable local prescribing information.
A patient should not start Tagrisso solely because they have lung cancer or because another person with a similar diagnosis has received the medicine. The treating oncologist must determine whether the patient meets the relevant criteria.
Dosage and Administration
The usual adult regimen described in official prescribing information for applicable indications is 80 mg orally once daily. The correct regimen and any modifications must be determined by the prescribing healthcare professional.
Patients should follow the prescription and the instructions supplied with their specific product.
Important considerations include taking the medicine according to the prescribed schedule, following the current patient leaflet for administration and food instructions, and avoiding double doses after a missed dose.
If a dose is missed or vomiting occurs after administration, patients should follow the product-specific instructions or contact their healthcare team. They should not automatically take another tablet or independently change their regimen.
Dose interruption, modification or discontinuation may be necessary in certain circumstances, including some adverse reactions. These decisions require professional assessment.
Potential Benefits of Tagrisso Treatment
The potential benefits depend on the clinical setting.
- After surgery: Adjuvant treatment may reduce the risk of recurrence in eligible patients.
- After definitive chemoradiation: Treatment may help control disease in selected patients with unresectable stage III NSCLC.
- In advanced disease: Treatment may help control tumor growth and delay disease progression.
- In selected molecular settings: Osimertinib may be appropriate when the tumor has a relevant EGFR mutation.
These potential benefits do not guarantee an individual outcome. The extent of benefit varies with tumor biology, treatment setting, previous therapies and other clinical factors.
Patients should ask their oncology team how the expected benefit will be assessed and which findings may influence future treatment decisions.
Common Side Effects of Tagrisso
Commonly reported adverse reactions include diarrhea, rash, dry skin, nail changes and inflammation of the mouth.
The severity of symptoms varies. Persistent diarrhea may lead to dehydration, while skin reactions and mouth sores can affect comfort and daily activities.
Patients should report symptoms that persist, worsen or interfere with eating, drinking, sleeping or other routine activities. The healthcare team can assess the problem and recommend appropriate management.
Patients should not start additional medicines, herbal remedies or supplements for side effects without checking their suitability with a qualified healthcare professional.
Serious Risks and Safety Precautions
Osimertinib can cause serious adverse reactions. Important risks include:
Interstitial lung disease or pneumonitis: New or worsening shortness of breath, persistent cough or unexplained respiratory symptoms require prompt medical assessment.
QT prolongation: Osimertinib may affect the heart’s electrical rhythm. Fainting, palpitations or a rapid or irregular heartbeat should be assessed promptly.
Cardiomyopathy: Changes in heart function may require investigation and additional monitoring.
Keratitis and other eye problems: Eye pain, redness, light sensitivity or visual changes should be reported promptly.
Aplastic anemia: Unusual bruising, unexplained bleeding, marked weakness or unusual infections warrant medical assessment.
Severe or rapidly worsening symptoms may require emergency medical assistance. Patients should not delay care while seeking information online.
Drug Interactions and Medical History
Before treatment begins, patients should tell their healthcare team about all prescription medicines, nonprescription products, vitamins, supplements and herbal remedies they use.
Some medicines may increase specific safety risks or require additional monitoring, particularly when they affect heart rhythm or have overlapping adverse effects.
Patients should also disclose relevant heart, lung and eye conditions, previous serious medicine reactions and any other significant medical history.
The oncology team or pharmacist can review potential interactions and determine whether additional precautions are appropriate. Patients should not independently stop other prescribed medicines or begin new supplements.
Pregnancy and Breastfeeding
Osimertinib may cause fetal harm. Patients who are pregnant, planning pregnancy or who think they may be pregnant should contact their healthcare professional promptly.
The treating clinician should explain the applicable pregnancy-prevention precautions and contraception requirements using the current official prescribing information.
Breastfeeding also requires medical advice because the medicine may pose risks to a nursing infant. Patients should discuss the applicable restrictions before starting treatment or changing their feeding plans.
Monitoring During Treatment
Ongoing monitoring helps the oncology team assess whether treatment is effective and whether adverse reactions require attention.
Depending on the indication and individual risk factors, monitoring may include clinical assessment, imaging studies, laboratory testing, electrocardiography or evaluation of heart function.
Patients should attend scheduled appointments, follow the monitoring plan and report new symptoms promptly. The clinician may adjust the plan as the patient’s condition changes.
Treatment response cannot be determined reliably from symptoms alone. Follow-up assessments help the oncology team evaluate the disease and decide whether the current treatment remains appropriate.
Frequently Asked Questions About Tagrisso 80 mg Uses
Is Tagrisso used for every type of lung cancer?
No. Tagrisso is used in specific treatment settings involving NSCLC with certain EGFR mutations. It is not appropriate for every lung cancer diagnosis.
Can Tagrisso be used after lung cancer surgery?
Yes, in an approved adjuvant setting for eligible patients with resected NSCLC harboring specified EGFR mutations. The oncology team determines eligibility.
Can Tagrisso be used for advanced lung cancer?
It may be used in certain locally advanced or metastatic EGFR-mutated NSCLC settings, subject to the applicable indication and patient eligibility.
Is Tagrisso always taken alone?
No. In certain approved first-line settings, osimertinib may be prescribed with pemetrexed and platinum-based chemotherapy. The appropriate regimen depends on the indication and clinical circumstances.
Does Tagrisso cure lung cancer?
A cure cannot be guaranteed. Depending on the treatment setting, the medicine may reduce recurrence risk or help control disease. Individual outcomes vary.
Can treatment be stopped when the cancer improves?
Patients should not stop treatment independently. The duration and management of therapy must be determined by the treating healthcare professional.
Conclusion
Tagrisso 80 mg contains osimertinib, a targeted anticancer medicine used in defined treatment settings for NSCLC associated with specific EGFR mutations. Its clinical role may include adjuvant treatment after surgery, treatment following definitive chemoradiation, or treatment of locally advanced or metastatic disease. Certain approved indications also permit combination treatment with chemotherapy.
Safe use requires appropriate molecular testing, individualized prescribing, awareness of adverse reactions and ongoing medical supervision. Patients should follow their prescribed regimen, attend monitoring appointments and seek prompt assessment for concerning symptoms.
Medical Disclaimer: This page is intended for general educational purposes only and does not replace professional medical advice, diagnosis, treatment or current official prescribing information. Approved indications, eligibility criteria and prescribing instructions may vary by jurisdiction. Tagrisso should be used only under the supervision of a qualified healthcare professional. Seek urgent medical assistance for severe or rapidly worsening symptoms.